Skip to content

Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

Use of Preemptive Pudendal Nerve Block Prior to Hydrodistension for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-blinded, Randomized Control Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02517996
Enrollment
18
Registered
2015-08-07
Start date
2015-02-28
Completion date
2018-06-30
Last updated
2019-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Cystitis, Painful Bladder Syndrome

Brief summary

Interstitial cystitis/Painful bladder syndrome (IC/PBS) is a chronic debilitating condition that severely impacts between 2.7 and 6.5 percent of women in the United States. Despite its public health importance the pathogenesis of IC/PBS is not well understood and there is no consensus on the optimal treatment approach for this condition. Hydrodistention is the most commonly used therapy for this condition; but it is limited by severe immediate postoperative bladder pain and its short duration of action. It has been postulated that hydrodistention works by disrupting the sensory nerves within the bladder that may be contributing to bladder pain. Recent evidence has provided support for the use of preemptive pudendal nerve block as a way to blunt immediate postoperative pain. The investigators hypothesize that preemptive pudendal nerve block prior to hydrodistention will result in lower postoperative pain after hydrodistention compared to placebo. This is a prospective double- blinded randomized study and patients will be randomized to receive preemptive bilateral pudendal nerve block with either 1% lidocaine or placebo. Bladder pain will be compared at baseline, 2 hours, 2 weeks, 6 weeks and 3 months using the Visual Analog Scale, O'Leary-Sant questionnaire and the Pelvic Pain Urgency and Frequency questionnaire.

Detailed description

Painful bladder syndrome/interstitial cystitis (IC/PBS) is a disorder characterized by chronic bladder pain or discomfort. The exact underlying etiology of IC/PBS is unknown however several theories exist which include epithelial dysfunction, mast cell activation, and neurogenic inflammation. Whatever the underlying inciting factor for IC/PBS, the resulting phenotype is one of urinary frequency, urgency and bladder pain improved after voiding. Animal studies show that as the normal bladder fills, mechanoreceptors in the bladder wall respond to stretch through the discharge of afferent innervations or nerve firing. In normal humans, there is no conscious perception that the bladder is filling until a threshold volume is reached4. Patients with PBS/IC are thought to have substantially lower cystometric bladder volumes and a heightened sensitivity to bladder filling. Mechanoreceptors and chemoreceptors in the bladder may trigger myelinated A- delta or C-fibers found in the smooth muscle or in the submucosa in response to bladder distention. A- delta fibers are distributed mainly within the detrusor smooth muscle and are responsive to detrusor stretch that occurs during bladder filling. In contrast, C-type fibers seem to be more widespread and are distributed in the detrusor muscle, within the lamina propria and in close proximity to the urothelium. There is considerable interest in mechanisms underlying sensitization of C-fiber afferents, as these nerves are thought to play a key role in symptoms of IC/PBS. It has been shown that the plexus of afferent nerves is most dense in the regions of the bladder neck and proximal urethra. Lumbosacral afferent fibers in the pelvic and pudendal nerve, with cell bodies in the lumbosacral dorsal root ganglion (DRG), not only sense pain but also regulate continence and micturition. In laboratory animals, the pelvic nerve supply contains more stretch-responsive afferent fibers and appears to be important in responses to bladder over-distention. Neurologic changes seen after the occurrence of cystitis or other bladder insult suggest reorganization of reflex connections in the spinal cord and changes to the bladder afferents, that may suggest a greater role for the influence of the pudendal nerve on bladder pain than had been previously thought. The pudendal nerve is a peripheral nerve that is mainly composed of afferent sensory fibers from sacral nerve roots S1, S2, and S3 and consequently it is a major contributor to bladder afferent regulation and bladder function. Pudendal nerve entrapment often leads to significant voiding dysfunction including urinary incontinence and over active bladder syndrome Furthermore, because the pudendal nerve carries such a large percentage of afferent fibers, it has been an attractive target for neuromodulation in treating refractory overactive bladder and may be useful for modulating pain experienced in IC/PBS. No treatment has been consistently shown to provide relief in the majority of patients with painful bladder syndrome. Furthermore, combination treatment modalities are needed in the majority of patients. Cystoscopy with hydrodistention is thought to be a useful therapeutic tool in patients who are unresponsive to therapies like medication and pelvic floor physical therapy; however, its use has only been studied in a few observational studies and is currently listed as a third line treatment option for IC/PBS. According to the interstitial cystitis database study experience cystoscopy with hydrodistention is reported to be the most commonly used treatment modality for IC/PBS and published studies have reported improvement in symptoms in 70 to 80 percent of patients while other studies have reported improvement in only 40 percent. It has been postulated that hydrodistention works by disrupting the sensory nerves within the bladder that may be contributing to bladder pain and enabling the regeneration of afferent sensory nerves. Though the exact mechanism of action is unclear, there is ample evidence to suggest the efficacy of cystoscopy with hydrodistention, in a recent study by Chien-Ying et al, therapeutic hydrodistension was associated with an increase in bladder capacity and significant reduction in average O'Leary- Sant symptom and problem scores after treatment. In addition, Aihara et al who determined a positive therapeutic outcome in 71% of patients 1 month after hydrodistention have reported similar findings. The disadvantages of hydrodistention are that some patients experience a temporary worsening of their symptoms immediately following the procedure and any beneficial effect often lasts between 2-6 weeks. The immediate worsening of bladder symptoms immediately after hydrodistention and its relatively short duration of effect are often deterrents to recommending this therapy to patients. Given the multimodal approach to managing patients with IC/PBS it is imperative that the investigators explore ways to prolong the efficacy of available options and one approach that has been recently suggested is the use of preemptive analgesia. In 1983, Woolf proposed that persistent pain experienced after trauma or surgery is due to posttraumatic functional changes not only in the peripheral pain receptors but also in the dorsal horn of the spinal cord a property known as hyperexcitability. The hyperexcitable state persists long after such stimuli cease, causing the patient to perceive pain from stimuli normally believed to be painless a common occurrence thought to be seen in patients with IC/PBS. Therefore, prevention of spinal hyperexcitability by blockade of the afferent nerve pathway from surgical site to spinal cord may therefore decrease the amount and duration of postoperative pain perception. This theory has been tested in various animal studies and was first described by Wall in 1988. In addition, the current literature on preemptive analgesia in gynecology is supportive of this approach. In a study by Ismail et al, 130 patients undergoing posterior colporrhaphy were randomized to receive preemptive pudendal nerve block with either .25% bupivacaine or normal saline. Study findings demonstrated an average postoperative Visual Analog Scale (VAS) score of 51.1 for the bupivacaine group compared to 23.5 in the placebo group. The investigators postulate that since the pudendal nerve is an important contributor to bladder afferent regulation, preemptive nerve block prior to hydrodistention may block afferent impulse transmission to the spinal cord and decrease the initial increase in postoperative bladder pain.

Interventions

DRUGLidocaine

Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.

DRUGPlacebo

Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All women aged greater than 18 years of age scheduled to undergo cystoscopy with hydrodistention * who are literate, * English speaking and * can provide written informed consent will be included in this study.

Exclusion criteria

* Patients who have intolerance or known allergies to local analgesia will be excluded. * In addition, patients who have coagulation disorders will also be excluded as this may increase their risks of complication from bleeding. * Patient will also be excluded if they have a history of dementia as this may impair their ability to follow instructions. * Patients who are non-ambulatory and who have an inability to fully assess pain will also be excluded. * Patients receiving additional surgical procedures will be excluded from the study, as the source of their pain may be difficult to decipher in the immediate post-operative period.

Design outcomes

Primary

MeasureTime frameDescription
Change in Pain Level as Assessed by the Visual Analog Scale (VAS)Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)To determine the change in pain at 2 hours, 2 weeks, 6 weeks, and 3 months postoperatively in patients undergoing hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline) using the visual analog scale (VAS). VAS consists of a 10cm horizontal line with the minimum endpoint labeled no pain (0) and maximum labeled worst pain ever (10). Patients placed a mark on the point that corresponds to the level of pain severity they felt. The cm distance from the low end of the VAS to the patient's mark is used as the numerical index of the intensity of pain. Pain scores of 3.0-5.4 cm are moderate, over 5.4 indicates severe pain.
Change in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to SalineBaseline, 2 weeks, 6 weeks, 3 months (Up to 3 months)To determine the change in interstitial cystitis symptom index at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline). The IC symptom index questionnaire consists of 4 questions on IC symptoms. 2 of the questions have 6 answer choices ranging from 0-never, to 5-almost always. 1 question has 6 answer choices ranging from 0-never to 5-usually. 1 question has 7 answer choices ranging from 0-never to 6-5 or more times. The numerical score for each question are added together, with a minimum score of 0 and a maximum score of 21. A higher score indicates greater severity of IC symptoms.
Change in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to SalineBaseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)To determine the change in problem index (O'Leary Sant) at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline). The IC problem index questionnaire consists of 4 questions on how much of a problem a patient's IC symptoms cause them. Each question has 5 answer choices ranging from 0-no problem, to 4-big problem. The numerical score for each question are added together, with a minimum score of 0 and a maximum score of 16. A higher score indicates that IC symptoms cause more problems for the patient.
Change in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to SalineBaseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)To determine the change in pelvic urgency, pain and frequency (PUF) questionnaire at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline). The Pelvic Urgency, Pain, and Frequency Patient Symptom Scale asks 11 questions, 7 on PUF symptoms, 4 on how bothersome PUF symptoms are. Symptom questions include 3, 4, or 5 ranked answers, with higher answers indicating more voids, or greater frequency of pain. The bother questions each of 4 ranked answers from 0-never, to 3-always. The symptom score is added, the bother score is added, and then the total score is added. The total PUF score is then reported. The minimum score is 0 and the maximum score is 35, and a higher score indicates greater symptoms and higher bother from pelvic pain and frequency.

Countries

United States

Participant flow

Recruitment details

Patients for this study are recruited either directly from the clinic of a Urogyn attending, or are identified the week before surgery on the OR schedule. The patients eligible for this study need to be posted for cystoscopy with hydrodistention for a diagnosis of bladder pain.

Pre-assignment details

1 woman was unmasked after her initial postoperative scores were collected because of postoperative symptoms.

Participants by arm

ArmCount
1% Lidocaine
Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters 1% lidocaine after anesthesia induction. Lidocaine: Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the postsynaptic neuron membrane will not depolarize and so fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
8
Normal Saline
Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction. Placebo: Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
9
Total17

Baseline characteristics

Characteristic1% LidocaineNormal SalineTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
8 Participants9 Participants17 Participants
Age, Continuous41.1 years39.7 years40.4 years
Number of other therapies3 Number of other therapies3 Number of other therapies3 Number of other therapies
Previous procedure5 Participants4 Participants9 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
5 Participants7 Participants12 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
3 Participants2 Participants5 Participants
Region of Enrollment
United States
8 participants9 participants17 participants
Sex: Female, Male
Female
8 Participants9 Participants17 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 80 / 9
other
Total, other adverse events
0 / 80 / 9
serious
Total, serious adverse events
0 / 80 / 9

Outcome results

Primary

Change in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline

To determine the change in interstitial cystitis symptom index at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline). The IC symptom index questionnaire consists of 4 questions on IC symptoms. 2 of the questions have 6 answer choices ranging from 0-never, to 5-almost always. 1 question has 6 answer choices ranging from 0-never to 5-usually. 1 question has 7 answer choices ranging from 0-never to 6-5 or more times. The numerical score for each question are added together, with a minimum score of 0 and a maximum score of 21. A higher score indicates greater severity of IC symptoms.

Time frame: Baseline, 2 weeks, 6 weeks, 3 months (Up to 3 months)

Population: Loss to follow up of 2 participants in the Normal Saline group

ArmMeasureGroupValue (MEAN)Dispersion
1% LidocaineChange in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline2 weeks11.43 score on a scaleStandard Deviation 4.72
1% LidocaineChange in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline12 weeks10 score on a scaleStandard Deviation 3.94
1% LidocaineChange in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline6 weeks11.8 score on a scaleStandard Deviation 3.83
1% LidocaineChange in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to SalineBaseline12.5 score on a scaleStandard Deviation 3.74
Normal SalineChange in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline2 weeks9 score on a scaleStandard Deviation 3.16
Normal SalineChange in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to SalineBaseline10 score on a scaleStandard Deviation 2.52
Normal SalineChange in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline6 weeks8.67 score on a scaleStandard Deviation 4.62
Normal SalineChange in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline12 weeks5 score on a scaleStandard Deviation 1.41
Primary

Change in Pain Level as Assessed by the Visual Analog Scale (VAS)

To determine the change in pain at 2 hours, 2 weeks, 6 weeks, and 3 months postoperatively in patients undergoing hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline) using the visual analog scale (VAS). VAS consists of a 10cm horizontal line with the minimum endpoint labeled no pain (0) and maximum labeled worst pain ever (10). Patients placed a mark on the point that corresponds to the level of pain severity they felt. The cm distance from the low end of the VAS to the patient's mark is used as the numerical index of the intensity of pain. Pain scores of 3.0-5.4 cm are moderate, over 5.4 indicates severe pain.

Time frame: Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)

Population: Loss to follow up of 2 participants in the Normal Saline group

ArmMeasureGroupValue (MEAN)Dispersion
1% LidocaineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)Post operative VAS score3.75 score on a scaleStandard Deviation 2.43
1% LidocaineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)6 week post operative VAS score3 score on a scaleStandard Deviation 3.31
1% LidocaineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)2 week post operative VAS scores2.7 score on a scaleStandard Deviation 2.68
1% LidocaineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)12 weeks post operative VAS score2.6 score on a scaleStandard Deviation 2.4
1% LidocaineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)Pre operative VAS score3.125 score on a scaleStandard Deviation 2.59
Normal SalineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)12 weeks post operative VAS score2 score on a scaleStandard Deviation 2.82
Normal SalineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)Pre operative VAS score4.5 score on a scaleStandard Deviation 2.5
Normal SalineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)Post operative VAS score5 score on a scaleStandard Deviation 1.73
Normal SalineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)2 week post operative VAS scores4.8 score on a scaleStandard Deviation 1.3
Normal SalineChange in Pain Level as Assessed by the Visual Analog Scale (VAS)6 week post operative VAS score4.33 score on a scaleStandard Deviation 2.1
Primary

Change in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline

To determine the change in pelvic urgency, pain and frequency (PUF) questionnaire at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline). The Pelvic Urgency, Pain, and Frequency Patient Symptom Scale asks 11 questions, 7 on PUF symptoms, 4 on how bothersome PUF symptoms are. Symptom questions include 3, 4, or 5 ranked answers, with higher answers indicating more voids, or greater frequency of pain. The bother questions each of 4 ranked answers from 0-never, to 3-always. The symptom score is added, the bother score is added, and then the total score is added. The total PUF score is then reported. The minimum score is 0 and the maximum score is 35, and a higher score indicates greater symptoms and higher bother from pelvic pain and frequency.

Time frame: Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)

Population: Loss to follow up of 3 participants in the Normal Saline group

ArmMeasureGroupValue (MEAN)Dispersion
1% LidocaineChange in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to SalineBaseline22.63 score on a scaleStandard Deviation 6.74
1% LidocaineChange in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline2 weeks18.83 score on a scaleStandard Deviation 7.99
1% LidocaineChange in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline6 weeks18.2 score on a scaleStandard Deviation 7.53
1% LidocaineChange in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline12 weeks17.2 score on a scaleStandard Deviation 6.61
Normal SalineChange in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline12 weeks14 score on a scale
Normal SalineChange in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to SalineBaseline19 score on a scaleStandard Deviation 4
Normal SalineChange in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline6 weeks16.7 score on a scaleStandard Deviation 3.21
Normal SalineChange in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline2 weeks17.4 score on a scaleStandard Deviation 4.72
Primary

Change in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to Saline

To determine the change in problem index (O'Leary Sant) at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline). The IC problem index questionnaire consists of 4 questions on how much of a problem a patient's IC symptoms cause them. Each question has 5 answer choices ranging from 0-no problem, to 4-big problem. The numerical score for each question are added together, with a minimum score of 0 and a maximum score of 16. A higher score indicates that IC symptoms cause more problems for the patient.

Time frame: Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)

Population: Loss to follow up of 2 participants in the Normal Saline group

ArmMeasureGroupValue (MEAN)Dispersion
1% LidocaineChange in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to SalineBaseline11.75 score on a scaleStandard Deviation 2.92
1% LidocaineChange in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to Saline2 weeks9.71 score on a scaleStandard Deviation 3.95
1% LidocaineChange in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to Saline6 weeks10 score on a scaleStandard Deviation 3.81
1% LidocaineChange in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to Saline12 weeks9.6 score on a scaleStandard Deviation 2.79
Normal SalineChange in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to Saline12 weeks6 score on a scaleStandard Deviation 2.83
Normal SalineChange in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to SalineBaseline9.43 score on a scaleStandard Deviation 3.1
Normal SalineChange in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to Saline6 weeks7.33 score on a scaleStandard Deviation 3.21
Normal SalineChange in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to Saline2 weeks8.6 score on a scaleStandard Deviation 2.07

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026